Founded in 2004, ERYTECH Pharma develops innovative cancer therapies that work by starving tumours. Its first product, which is in phase III development, provides a therapeutic solution to frail patients with acute leukaemia.

ERYTECH proprietary technology is based on encapsulation of therapeutic molecules into red blood cells.

The company has a production unit located in Lyons with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.

news

> Show all

23/10/2014

ERYTECH successfully raises €30 million for expanding its therapeutic indications in oncology and accelerating its clinical developments

20/10/2014

ERYTECH announces the granting of a new patent in the field of asparaginase in the United States.

09/10/2014

ERYTECH wins EuropaBio’s Most Innovative European Biotech SME Award 2014

30/09/2014

ERYTECH reports positive Phase III results from its pivotal study with GRASPA® in Acute Lymphoblastic Leukemia.

diary

> Show all

November 24 - 26, 2014

FINANCE – ERYTECH Pharma attends German Equity Forum from November 24 to 26, 2014 in Frankfurt, Germany.

November 21 & 22, 2014

FINANCE – ERYTECH Pharma participates in Actionaria 2014 on November 21 & 22, 2014 in Paris, France.

November 19 & 20, 2014

FINANCE – ERYTECH Pharma takes part in Jefferies Global Healthcare Conference on November 19 & 20, 2014 in London, UK.

November 3 - 5, 2014

ERYTECH Pharma participates in Bio Europe 2014 from November 3 to 5 in Frankfurt, Germany.